Personalis Inc (PSNL)

09:05 AM

What drives Personalis Inc. stock priceMassive profits - Autocar Professional

09:05 AM

03:28 AM

Is Personalis Inc. a good long term investmentFree Stock Market Forecast Reports - Autocar Professional

03:28 AM

Jul 19, 2025

Personalis Inc. Stock Analysis and ForecastExplosive trading opportunities - Jammu Links News

Jul 19, 2025

Jul 19, 2025

What analysts say about Personalis Inc. stockFree Wealth Management Insights - Jammu Links News

Jul 19, 2025

Jul 18, 2025

Personalis Strengthens Leadership: New VP Gets $631K Stock Option Package in Precision Oncology Push - Stock Titan

Jul 18, 2025

Jul 18, 2025

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PSNL Stock News - GuruFocus

Jul 18, 2025

Jul 18, 2025

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Jul 18, 2025

Jul 17, 2025

Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer - Insider Monkey

Jul 17, 2025

Jul 16, 2025

From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine - Benzinga

Jul 16, 2025

Jul 15, 2025

How Personalis Inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser

Jul 15, 2025

Jul 15, 2025

Why Personalis Inc. stock attracts strong analyst attentionFree Insider Trading Tips - Newser

Jul 15, 2025

Jul 15, 2025

What makes Personalis Inc. stock price move sharplyFree Investment Group - Newser

Jul 15, 2025

Jul 12, 2025

Personalis (NASDAQ:PSNL) Pulls Back 14% This Week, but Still Delivers Shareholders Splendid 284% Return Over 1 Year - 富途牛牛

Jul 12, 2025

Jul 11, 2025

Personalis, Inc. (PSNL) Stock Analysis: Navigating a 5.50% Revenue Growth Amidst Volatility - DirectorsTalk Interviews

Jul 11, 2025

Jul 10, 2025

Personalis (PSNL) Expands Partnership with Tempus AI for Cancer Detection - GuruFocus

Jul 10, 2025

Jul 10, 2025

Personalis and Tempus: Pioneering the Future of Colorectal Cancer Care Through Precision Diagnostics - AInvest

Jul 10, 2025

Jul 10, 2025

Personalis expands Tempus deal to include colorectal cancer testing - Seeking Alpha

Jul 10, 2025

Jul 10, 2025

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients - businessnewsthisweek.com

Jul 10, 2025

Jul 09, 2025

Personalis and Tempus extend cancer detection collaboration to 2029 By Investing.com - Investing.com South Africa

Jul 09, 2025

Jul 09, 2025

Personalis and Tempus: A Cancer Detection Breakthrough with Multi-Billion-Dollar Implications - AInvest

Jul 09, 2025

Jul 09, 2025

Personalis extends Tempus agreement to add colorectal cancer indication By Investing.com - Investing.com South Africa

Jul 09, 2025

Jul 09, 2025

Personalis and Tempus extend cancer detection collaboration to 2029 - Investing.com Australia

Jul 09, 2025

Jul 09, 2025

Personalis Expands Tempus Strategic Collaboration to Bring Ultra - GuruFocus

Jul 09, 2025

Jul 09, 2025

Personalis extends Tempus agreement to add colorectal cancer indication - Investing.com

Jul 09, 2025

Jul 09, 2025

Personalis Expands Agreement with Tempus AI for Cancer Test - TipRanks

Jul 09, 2025

Jul 09, 2025

Personalis Expands Tempus AI Collaboration to Include Colorectal Cancer - HIT Consultant

Jul 09, 2025

Jul 09, 2025

Personalis Expands Tempus AI Collaboration to Include Colorectal Cancer Detection - MarketScreener

Jul 09, 2025

Jul 09, 2025

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-S Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients - MarketScreener

Jul 09, 2025

Jul 07, 2025

Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains? - MSN

Jul 07, 2025

Jul 05, 2025

Supernus Pharmaceuticals (NASDAQ:SUPN) & Personalis (NASDAQ:PSNL) Financial Comparison - Defense World

Jul 05, 2025

Jun 30, 2025

Personalis, Inc.(NasdaqGM: PSNL) added to Russell Small Cap Completeness Index - MarketScreener

Jun 30, 2025

Jun 30, 2025

Personalis, Inc.(NasdaqGM: PSNL) added to Russell 3000 Index - MarketScreener

Jun 30, 2025